eMedicine Specialties > Dermatology > Benign Neoplasms

Nevi of Ota and Ito

Author: Harvey Lui, MD, FRCPC, Professor and Head, Department of Dermatology and Skin Science, Vancouver General Hospital, University of British Columbia; Medical Director, The Skin Centre, Lions Laser Skin Centre and Psoriasis and Phototherapy Clinic, Vancouver General Hospital
Coauthor(s): Youwen Zhou, MD, PhD, FRCP(C), Associate Professor, Department of Dermatology and Skin Science, University of British Columbia; Director, Hyperhidrosis Specialty Clinic, Co-Director, Psoriasis and Phototherapy Centre, Consulting Physician, Department of Dermatology, Vancouver General Hospital, Co-Director, Vitiligo and Pigmentation Clinic, Oncologist Consultant, Skin Tumor Program, BC Cancer Agency
Contributor Information and Disclosures

Updated: Jul 14, 2008

Introduction

Background

Nevus of Ota, which originally was described by Ota and Tanino in 1939, is a hamartoma of dermal melanocytes. Clinically, nevus of Ota presents as a blue or gray patch on the face, which is congenital or acquired and is within the distribution of the ophthalmic and maxillary branches of the trigeminal nerve. The nevus can be unilateral or bilateral, and, in addition to skin, it may involve ocular and oral mucosal surfaces.

Nevus of Ito, initially described by Minor Ito1 in 1954, is a dermal melanocytic condition affecting the shoulder area. Nevus of Ito often occurs in association with nevus of Ota in the same patient but is much less common, although the true incidence is unknown.

Additionally, the eMedicine article Nevi, Melanocytic may be of interest.

Pathophysiology

The etiology and pathogenesis of nevi of Ota and Ito are not known. Although unconfirmed, nevus of Ota and other dermal melanocytic disorders, such as nevus of Ito, blue nevus, and mongolian spots, may represent melanocytes that have not migrated completely from the neural crest to the epidermis during the embryonic stage. The variable prevalence among different populations suggests genetic influences, although familial cases of nevus of Ota are exceedingly rare. The 2 peak ages of onset in early infancy and in early adolescence suggest that hormones are a factor in the development of this condition. The observation of dermal melanocytes in close proximity with nerve bundles in nevus of Ito suggests that the nervous system is a factor in the development of nevus of Ito, although the true pathogenesis remains unknown.

Mortality/Morbidity

Nevus of Ota can cause facial disfigurement, resulting in emotional and psychologic distress. In rare cases, melanoma, which can be life threatening, has been reported to arise from nevus of Ota. Glaucoma also has been associated with nevus of Ota.

Nevus of Ito usually does not have symptoms and causes little cosmetic concern to the patients; however, sensory changes occasionally are present in the lesion.

Race

  • Nevi of Ota and Ito occur most frequently in Asian populations, with an estimated prevalence of 0.2-0.6% for nevus of Ota in Japanese persons. Nevus of Ito is less common than nevus of Ota, although the true incidence is unknown.
  • Other ethnic groups with increased prevalence include Africans, African Americans, and East Indians.
  • Nevi of Ota and Ito are uncommon in whites.

Sex

  • Male-to-female ratio is 1:4.8 for nevus of Ota. The ratio for nevus of Ito is unknown.

Age

  • The first peak of onset of nevus of Ota occurs in infancy, with as many as 50% of nevus of Ota cases present at birth. The onset for nevus of Ito is at birth or shortly after.
  • The second peak of onset for nevus of Ota is seen during adolescence.
  • Isolated cases of delayed-onset nevi of Ota that first appear in adults, including in older patients, have been reported.

Clinical

History

After onset, nevus of Ota may slowly and progressively enlarge and darken in color, and its appearance usually remains stable once adulthood is reached. The color or perception of the color of nevus of Ota may fluctuate according to personal and environmental conditions, such as fatigue, menstruation, insomnia, and cloudy, cold, or hot weather conditions. Nevus of Ota can be associated with other cutaneous disorders and ocular disease. Nevus of Ito can be associated with sensory changes in the involved skin.

  • Benign cutaneous and leptomeningeal conditions associated with nevus of Ota
    • Nevus of Ito
    • Phakomatosis pigmentovascularis
    • Nevus flammeus
    • Sturge-Weber syndrome
    • Neurofibromatosis and leptomeningeal melanosis
  • Malignant melanoma
    • More than 60 cases of malignant melanoma (56 in whites, 4 in Japanese) in association with nevus of Ota have been described in the literature as follows2 :
      • Skin - 10 cases
      • Meninges - 12 cases
      • Ocular tissues - 40 cases
    • To date, only 1 case of malignant degeneration of nevus of Ito has been described and involved a 78-year-old white man.3
  • Ocular abnormalities (ocular acuity normal)
    • Pigmentation of the sclera, cornea, retina, and optic disc
    • Cavernous hemangiomas of the optic disc
    • Elevated intraocular pressure
    • Glaucoma (10.3%)4
    • Ocular melanoma

Physical

Clinical and Histologic Features for Differential Diagnoses of Nevi of Ota and Ito

Open table in new window

Table
ConditionOnsetAppearanceLocationHistology
Nevi of Ota and ItoBirth or early adolescenceBlue or gray speckled coalescing macules or patchesFor nevus of Ota, unilateral, rarely bilateral, on forehead, temple, zygomatic, or periorbital areas; for nevus of Ito, the shoulder and upper arm areasIncreased dermal melanocytes, with surrounding fibrosis and melanophages
Mongolian spotBirthPoorly demarcated large blue-to-gray patches that tend to spontaneously resolve by age 3-6 yMost frequently on lumbosacral areas, buttocks, and rarely, other areasIncreased dermal melanocytes; no surrounding fibrosis
Blue nevusCongenital or acquiredBlue papules or plaquesAnywhere on skinDermal nodular proliferation of heavily pigmented spindle cells
MelasmaAcquired; may be associated with pregnancy and other estrogen excess stagesWell-to-poorly demarcated and irregularly outlined brown-to-gray brown patchesMaxillary and zygomatic areas on faceNo increase in dermal melanocytes; presence of melanophages
Lentigo malignaAcquired; presenting usually after fifth decade of lifeBrown patches, usually with pigmentary variegationPhotodistribution, particularly within zygomaticomaxillary areasAtypical melanocytes in nests at dermal-epidermal junction, with pagetoid spread
Actinic lentigoAcquired; usually after fifth decade of lifeWell-demarcated brown papules or plaquesPhotodistribution, especially on faceElongation of rete ridges; basal layer hyperpigmentation; slight increase of melanocyte number along basal layer
PhytophotodermatitisAcquired; exposure to certain plants or cosmeticsGray-to-brown macules and patchesPhotodistribution, according to sites of contact with photosensitizerDermal melanophages
Drug-induced hyperpigmentationAcquired; following drug exposure (eg, minocycline, amiodarone, gold)Variable according to offending drugsVariable according to specific offending drugsVariable but may involve presence of dermal melanophages; pigmentation of basal keratinocytes
Exogenous ochronosis (rare)Adulthood; following topical application of hydroquinoneIrregularly shaped blue-to-gray patches or maculesAreas corresponding to exposure to hydroquinoneYellow banana-shaped spindle cells in papillary dermis
Ochronosis (alkaptonuria, rare)First decade of lifeBlue-gray discoloration of ear cartilage, tip of nose, and scleraSymmetrical distribution over cartilage, nose, cheeks, and extensor tendons of hands, as well as flexural areasYellow-to-brown pigmentary granules within dermal macrophages
ConditionOnsetAppearanceLocationHistology
Nevi of Ota and ItoBirth or early adolescenceBlue or gray speckled coalescing macules or patchesFor nevus of Ota, unilateral, rarely bilateral, on forehead, temple, zygomatic, or periorbital areas; for nevus of Ito, the shoulder and upper arm areasIncreased dermal melanocytes, with surrounding fibrosis and melanophages
Mongolian spotBirthPoorly demarcated large blue-to-gray patches that tend to spontaneously resolve by age 3-6 yMost frequently on lumbosacral areas, buttocks, and rarely, other areasIncreased dermal melanocytes; no surrounding fibrosis
Blue nevusCongenital or acquiredBlue papules or plaquesAnywhere on skinDermal nodular proliferation of heavily pigmented spindle cells
MelasmaAcquired; may be associated with pregnancy and other estrogen excess stagesWell-to-poorly demarcated and irregularly outlined brown-to-gray brown patchesMaxillary and zygomatic areas on faceNo increase in dermal melanocytes; presence of melanophages
Lentigo malignaAcquired; presenting usually after fifth decade of lifeBrown patches, usually with pigmentary variegationPhotodistribution, particularly within zygomaticomaxillary areasAtypical melanocytes in nests at dermal-epidermal junction, with pagetoid spread
Actinic lentigoAcquired; usually after fifth decade of lifeWell-demarcated brown papules or plaquesPhotodistribution, especially on faceElongation of rete ridges; basal layer hyperpigmentation; slight increase of melanocyte number along basal layer
PhytophotodermatitisAcquired; exposure to certain plants or cosmeticsGray-to-brown macules and patchesPhotodistribution, according to sites of contact with photosensitizerDermal melanophages
Drug-induced hyperpigmentationAcquired; following drug exposure (eg, minocycline, amiodarone, gold)Variable according to offending drugsVariable according to specific offending drugsVariable but may involve presence of dermal melanophages; pigmentation of basal keratinocytes
Exogenous ochronosis (rare)Adulthood; following topical application of hydroquinoneIrregularly shaped blue-to-gray patches or maculesAreas corresponding to exposure to hydroquinoneYellow banana-shaped spindle cells in papillary dermis
Ochronosis (alkaptonuria, rare)First decade of lifeBlue-gray discoloration of ear cartilage, tip of nose, and scleraSymmetrical distribution over cartilage, nose, cheeks, and extensor tendons of hands, as well as flexural areasYellow-to-brown pigmentary granules within dermal macrophages


  • Nevus of Ota most frequently presents as blue-to-gray speckled or mottled coalescing macules or patches affecting the forehead, temple, malar area, or periorbital skin. Nevus of Ito presents as a patch on the shoulder or upper arms with blue, gray, or brown pigmentation.
    • Most cases of nevus of Ota are unilateral (90%), although pigmentation is present bilaterally in 5-10%. Nevus of Ito usually is unilateral.
    • In addition to skin, pigmentation of nevus of Ota may involve oral mucosa and ocular structures such as the sclera, retrobulbar fat, cornea, and retina.
  • Clinically, nevus of Ito is similar to nevus of Ota, except that it typically presents over the shoulder girdle region.
  • Specific variants of nevus of Ota have been described in the literature under the names of nevus fuscoceruleus zygomaticus, plaque-type variant of blue nevus, or Hori nevus. Some clinicians consider Hori nevus to be a distinct entity that is separate from nevus of Ota. Differential features of these conditions are related to the following:
    • Location of patch or macules
    • Extent of involvement
    • Age of onset
    • Tendency to occur as familial cases
    • Presence of a papular component
  • Pathology and response to therapy appear similar for all forms of nevus of Ota. The pathology of nevus of Ito is similar to that of nevus of Ota.

Causes

The cause of nevi of Ota and Ito is unknown.

More on Nevi of Ota and Ito

Overview: Nevi of Ota and Ito
Differential Diagnoses & Workup: Nevi of Ota and Ito
Treatment & Medication: Nevi of Ota and Ito
Follow-up: Nevi of Ota and Ito
References

References

  1. Ito M. Studies on melanin XXII. Nevus fuscocaeruleus acromio-deltoideus. Tohoko J Exper Med. 1954;60:10.

  2. Patel BC, Egan CA, Lucius RW, Gerwels JW, Mamalis N, Anderson RL. Cutaneous malignant melanoma and oculodermal melanocytosis (nevus of Ota): report of a case and review of the literature. J Am Acad Dermatol. May 1998;38(5 Pt 2):862-5. [Medline].

  3. van Krieken JH, Boom BW, Scheffer E. Malignant transformation in a naevus of Ito. A case report. Histopathology. Jan 1988;12(1):100-2. [Medline].

  4. Teekhasaenee C, Ritch R, Rutnin U, Leelawongs N. Glaucoma in oculodermal melanocytosis. Ophthalmology. May 1990;97(5):562-70. [Medline].

  5. Hirayama T, Suzuki T. A new classification of Ota's nevus based on histopathological features. Dermatologica. 1991;183(3):169-72. [Medline].

  6. Anderson RR. Lasers in dermatology--a critical update. J Dermatol. Nov 2000;27(11):700-5. [Medline].

  7. Watanabe S, Takahashi H. Treatment of nevus of Ota with the Q-switched ruby laser. N Engl J Med. Dec 29 1994;331(26):1745-50. [Medline].

  8. Chan HH, Leung RS, Ying SY, Lai CF, Kono T, Chua JK, et al. A retrospective analysis of complications in the treatment of nevus of Ota with the Q-switched alexandrite and Q-switched Nd:YAG lasers. Dermatol Surg. Nov 2000;26(11):1000-6. [Medline].

  9. Wang HW, Liu YH, Zhang GK, Jin HZ, Zuo YG, Jiang GT, et al. Analysis of 602 Chinese cases of nevus of Ota and the treatment results treated by Q-switched alexandrite laser. Dermatol Surg. Apr 2007;33(4):455-60. [Medline].

  10. Hosaka Y, Onizuka T, Ichinose M, Yoshimoto S, Okubo F, Hori S, et al. Treatment of nevus Ota by liquid nitrogen cryotherapy. Plast Reconstr Surg. Apr 1995;95(4):703-11. [Medline].

  11. Hidano A, Kajima H, Ikeda S, Mizutani H, Miyasato H, Niimura M. Natural history of nevus of Ota. Arch Dermatol. Feb 1967;95(2):187-95. [Medline].

Further Reading

Keywords

hamartoma, nevus of Ota, nevus of Ito, Hori nevus, Hori's nevus, nevus fuscoceruleus zygomaticus, plaque-type variant of blue nevus, nevus fuscoceruleus acromiodeltoideus

Contributor Information and Disclosures

Author

Harvey Lui, MD, FRCPC, Professor and Head, Department of Dermatology and Skin Science, Vancouver General Hospital, University of British Columbia; Medical Director, The Skin Centre, Lions Laser Skin Centre and Psoriasis and Phototherapy Clinic, Vancouver General Hospital
Harvey Lui, MD, FRCPC is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, American Society for Laser Medicine and Surgery, American Society for Photobiology, Canadian Dermatology Association, Canadian Dermatology Foundation, Canadian Medical Association, College of Physicians and Surgeons of British Columbia, Dermatology Foundation, European Academy of Dermatology and Venereology, National Psoriasis Foundation, North American Hair Research Society, and Photomedicine Society
Disclosure: Astellas Consulting fee Review panel membership; Amgen/Wyeth Consulting fee Speaking and teaching; LEO Pharma Honoraria Speaking and teaching; LEO Pharma Grant/research funds Investigator; Serono Grant/research funds Investigator; Galderma Grant/research funds Other

Coauthor(s)

Youwen Zhou, MD, PhD, FRCP(C), Associate Professor, Department of Dermatology and Skin Science, University of British Columbia; Director, Hyperhidrosis Specialty Clinic, Co-Director, Psoriasis and Phototherapy Centre, Consulting Physician, Department of Dermatology, Vancouver General Hospital, Co-Director, Vitiligo and Pigmentation Clinic, Oncologist Consultant, Skin Tumor Program, BC Cancer Agency
Youwen Zhou, MD, PhD, FRCP(C) is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

Medical Editor

Sungnack Lee, MD, Vice President of Medical Affairs, Professor, Department of Dermatology, Ajou University School of Medicine, Korea
Sungnack Lee, MD is a member of the following medical societies: American Dermatological Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Christen M Mowad, MD, Associate Professor, Department of Dermatology, Geisinger Medical Center
Christen M Mowad, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Phi Beta Kappa
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System
William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology
Disclosure: elsevier Royalty Other; american college of physicians Honoraria Other

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.